Breast Cancer

Data on FASLODEX Injection presented at symposium

Published in Women's Health Weekly, January 13th, 2005

Important new data from two phase II studies evaluating FASLODEX (fulvestrant) Injection as treatment for postmenopausal women with advanced breast cancer, who have experienced disease progression on aromatase inhibitor therapy, were presented at the San Antonio Breast Cancer Symposium (SABCS).

The first of the two studies, conducted by Dr. L. Perey from the Swiss Group for Clinical Cancer Research (SAKK) in Bern, Switzerland, evaluated treatment with FASLODEX in 67 postmenopausal women with advanced breast cancer who had previously responded to aromatase inhibitor treatment but had experienced disease progression. In this study, 19 patients (28%) experienced a partial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-01-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry